Quang X. Pham - 29 Jun 2026 Form 4 Insider Report for Cadrenal Therapeutics, Inc. (CVKD)

Reporting relationship: Chairman and CEO, Director, 10%+ Owner
Issuer ticker: CVKD
Reported as of: 29 Jun 2026
Net transaction value: -$22,422
SEC form: 4
Accepted by SEC: 01 Jul 2026, 21:52:04 UTC
Prior SEC filing: 26 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Quang X. Pham

Key filing fact

Quang X. Pham filed Form 4 for Cadrenal Therapeutics, Inc. (CVKD) on 01 Jul 2026.

Key facts

This page summarizes Quang X. Pham's Form 4 filing for Cadrenal Therapeutics, Inc. (CVKD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Jul 2026, 21:52.

Change

Previous filing in this sequence was filed on 26 Jun 2026.
Current net transaction value: -$22,422.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001405290 Primary reporting owner

Pham Quang X

Relationship: Chairman and CEO, Director, 10%+ Owner
Address: C/O CADRENAL THERAPEUTICS, INC., 822 A1A NORTH, SUITE 306, PONTE VEDRA
Signature: /s/ Quang X. Pham
Signature date: 01 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CVKD transaction

Common Stock

Sale

Transaction value: $22,422
Shares: -7,400
Change %: -7%
Price: $3.03
Shares after: 98,589
Date: 29 Jun 2026
Ownership: Direct
Footnotes: F1, F2

CVKD holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 200,000
Date: 29 Jun 2026
Ownership: The PVBQ Living Trust
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 through $3.13. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.